{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:44:28Z","timestamp":1794375868643,"version":"4.9.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:p>In the spectrum of allergic eye disease, vernal keratoconjunctivitis (VKC) is classed as one of the most severe disease entities and can have profound effects on visual development as well as on the emotional and psychological well-being of afflicted children. The traditional mainstay of treatment for the condition, to control the ocular inflammation, has been steroids but the use of these drugs has not been without side effects. Ciclosporin offers an alternative to steroids, providing symptom relief and control of the ocular inflammation, whilst averting the problems associated with raised intraocular pressure, cataract formation and reactivation of herpes simplex keratitis, all recognised side effects of topical steroids. However, the journey to the development of a formulation of an unpreserved ciclosporin for use in human eyes has been a protracted one; the aim of this article is to outline this journey and the role of ciclosporin in the modern management of this debilitating disease.<\/jats:p>","DOI":"10.3389\/fopht.2025.1525868","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:22:43Z","timestamp":1745558563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The evolving role of ciclosporin in the management of vernal keratoconjunctivitis"],"prefix":"10.3389","volume":"5","author":[{"given":"Mumta","family":"Kanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Manzouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3928\/01913913-20220328-01","article-title":"Management of vernal keratoconjunctivitis in children in the United Kingdom: A review of the literature and current best practice across six large United Kingdom centers","volume":"60","author":"Ghauri","year":"2023","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-016-0185-1","article-title":"An update on the therapeutic approach to vernal keratoconjunctivitis","volume":"18","author":"Esposito","year":"2016","journal-title":"Pediatr Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2249.2008.03716.x","article-title":"Allergy and the eye","volume":"153","author":"Leonardi","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3928\/01913913-20210319-01","article-title":"Understanding the journey of patients with vernal keratoconjunctivitis: A qualitative study of the impact on children and families","volume":"58","author":"Ghauri","year":"2021","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.4103\/ijo.IJO_2143_18","article-title":"Pattern of steroid misuse in vernal keratoconjunctivitis resulting in steroid induced glaucoma and visual disability in Indian rural population: An important public health problem in pediatric age group","volume":"67","author":"Sen","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/life14030361","article-title":"Vernal keratoconjunctivitis: immunopathological insights and therapeutic applications of immunomodulators","volume":"14","author":"Hehar","year":"2024","journal-title":"Life"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/all.15128","article-title":"Allergic eye disease: Blocking LTB4\/C5 in vivo suppressed disease and Th2 & Th9 cells","volume":"77","author":"Eskandarpour","year":"2022","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12016-023-08970-4","article-title":"Vernal keratoconjunctivitis: A systematic review","volume":"65","author":"Bruschi","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S129552","article-title":"Vernal keratoconjunctivitis","volume":"12","author":"Addis","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2013.12.002","article-title":"Immunosuppressive peptides and their therapeutic applications","volume":"19","author":"Thell","year":"2014","journal-title":"Drug Discovery Today"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399400001769","article-title":"Molecular targets for existing and novel immunosuppressive drugs","volume":"2","author":"Stepkowski","year":"2000","journal-title":"Expert Rev Mol Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1167\/iovs.13-11681","article-title":"Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A","volume":"54","author":"Gao","year":"2013","journal-title":"Investig Opthalmology Vis Sci"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.5772\/27484","article-title":"Systemic cyclosporin in the treatment of psoriasis","volume-title":"Psoriasis","author":"Colombo","year":"2012"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91970-0","article-title":"Cyclosporin A in patients receiving renal allografts from cadaver donors","volume":"312","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.221.4617.1273.a","article-title":"Britain joins european nations on fast breeder","volume":"221","author":"Dickson","year":"1983","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","article-title":"Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts","volume":"117","author":"Lallemand","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"B18","unstructured":"The top 300 of 2021"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.74.6.350","article-title":"Ocular penetration of cyclosporin A. III: The human eye","volume":"74","author":"BenEzra","year":"1990","journal-title":"Br J Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90356-5","article-title":"Side effects of systemic cyclosporine in patients not undergoing transplantation","volume":"77","author":"Palestine","year":"1984","journal-title":"Am J Med"},{"key":"B21","article-title":"Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection","volume":"45","author":"Hunter","year":"1981","journal-title":"Clin Exp Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/archopht.1989.01070020276038","article-title":"Spontaneous canine keratoconjunctivitis sicca: A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops","volume":"107","author":"Kaswan","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-199307000-00007","article-title":"Pilot trial of cyclosporine 1% Ophthalmic ointment in the treatment of keratoconjunctivitis sicca","volume":"12","author":"Laibovitz","year":"1993","journal-title":"Cornea"},{"key":"B24","volume-title":"Drug approval package: restasis cyclosporine ophthalmic emulsion","year":"2005"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.2147\/OPTH.S228070","article-title":"A review of topical cyclosporine A formulations\u2014A disease-modifying agent for keratoconjunctivitis sicca","volume":"14","author":"Jerkins","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease11Reprint requests to: Linda Lewis, 575 Anton Blvd, Suite 900, Costa Mesa, CA 92626","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.882803","article-title":"Comparison of seven cyclosporine A formulations for dry eye disease: A systematic review and network meta-analysis","volume":"13","author":"Gao","year":"2022","journal-title":"Front Pharmacol"},{"key":"B28","volume-title":"Full prescribing information","year":"2018"},{"key":"B29","volume-title":"Drug approval package: vevye","year":""},{"key":"B30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","article-title":"A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease","volume":"126","author":"Wirta","year":"2019","journal-title":"Ophthalmology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12075","article-title":"Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery","volume":"66","author":"Daull","year":"2014","journal-title":"J Pharm Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/ph14070658","article-title":"Immunopharmacology in vernal keratoconjunctivitis: current and future perspectives","volume":"14","author":"Chigbu","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02342-6","article-title":"Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials","volume":"37","author":"Leonardi","year":"2023","journal-title":"Eye"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.12.027","article-title":"A randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis","volume":"126","author":"Leonardi","year":"2019","journal-title":"Ophthalmology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1038\/s41598-025-85256-z","article-title":"Corticosteroid-sparing topical treatment with cyclosporiin for juvenile keratoconjunctivits","author":"Barcsay-Veres","year":"2025","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001040","article-title":"Steroid-sparing effect of ciclosporin A 1 mg\/mL: 5-year case series of 107 children and young people with vernal keratoconjunctivitis","volume":"7","author":"Dahlmann-Noor","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"key":"B37","unstructured":""}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1525868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:22:46Z","timestamp":1745558566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1525868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":37,"alternative-id":["10.3389\/fopht.2025.1525868"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2025.1525868","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1525868"}}